VISTA PHARMACEUTICALS LTD.

Vista Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The trading window will be closed from July 1, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. All designated persons and their immediate relatives are prohibited from trading in the company's shares during this period. The date of the board meeting to consider these financial results will be communicated later.

Vista Pharmaceuticals Ltd's board meeting on May 29, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board also approved the appointment of M/s. LMN & Co., Chartered Accountants, as Internal Auditors for the Financial Year 2026-27. The statutory auditors, M/s. A.M Reddy & D.R. Reddy, issued an audit report with an unmodified opinion on the financial results.

Vista Pharmaceuticals Ltd has announced a meeting of its Board of Directors scheduled for May 29, 2026. The meeting will address the approval of audited financial results for the quarter and year ended March 31, 2026, along with the audit report for the same period. Other business matters may also be discussed with the Chair's permission.

Vista Pharmaceuticals Ltd, with scrip code 524711, has announced the closure of its trading window for all designated employees, directors, and officers. The closure will be in effect from 1st April, 2026, and will reopen 48 hours after the declaration of audited financial results for the quarter and year ending 31.03.2026. The exact date of the board meeting for considering the said audited financial results will be intimated in due course.

Vista Pharmaceuticals Limited reported its financial results for the quarter and nine months ended 31st December 2025, according to the Listing Obligations and Disclosure requirements regulations, 2015. The company's revenue for the current quarter was Rs. 241.82 Lakhs, compared to Rs. 255.50 Lakhs for the corresponding quarter of the previous year. The company recognized a provision for Expected Credit Loss (ECL) amounting to INR 205.43 lakhs against its long-pending trade receivables. The company incurred a net loss for the quarter ended 31st December amounting to Rs. (838.25) Lakhs, and has outstanding statutory liabilities which have not been paid as on the quarter end.

Vista Pharmaceuticals Ltd. has reported its unaudited financial results for the quarter and nine months ended 31st December 2025. The company's total revenue for the current quarter is Rs. 241.82 Lakhs, a decrease from Rs. 255.50 Lakhs in the corresponding quarter of the previous year. The company has recognized a provision for Expected Credit Loss (ECL) amounting to INR 205.43 lakhs against its long-pending trade receivables. The company has incurred a net loss for the quarter ended 31st December amounting to Rs. (838 25) Lakhs, resulting in a Basic Earnings Per Share (EPS) of * (1.05) per equity share. The company has outstanding statutory liabilities which have not been paid as on the quarter end, including Tax Deducted at Source (TDS) payable, Employees’ State Insurance payable, Professional Tax payable, Provident Fund payable, and Income Tax payable. The company intends to clear these dues in subsequent periods.

Vista Pharmaceuticals Ltd. has revised the date of its Board Meeting, originally scheduled for 23/02/2026, to 13/02/2026. The meeting will take place at the company's registered office and will consider unaudited financial results for the quarter and nine months ended 31.12.2025, as well as the Limited Review Report for the same period. Any other business may be discussed with the chair's permission.

Vista Pharmaceuticals Ltd has announced that its Board of Directors will meet on February 13, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended 31.12.2025. The meeting will also discuss the Limited Review Report for the same period. Any other business with the permission of the Chair will also be considered.

Vista Pharmaceuticals Limited has formed a joint venture partnership with Pleiades Therapeutics to collaboratively develop Generic Drug Products and Specialty Pharmaceutical Products for regulated and rest-of-the-world markets. The strategic partnership aims to leverage Pleiades Therapeutics' R&D expertise with Vista Pharmaceuticals' robust manufacturing and established marketing presence in the United States and other key pharmaceutical markets. This collaboration is expected to enhance operational capabilities, expand market reach, and strengthen the competitive positioning of both companies in the global pharmaceutical industry.

Vista Pharmaceuticals Limited (Scrip Code: 524711) has announced that its trading window will be closed from January 1, 2026, for dealing in the Securities of the Company. The closure is in accordance with the Company's minimum Standards Code of Conduct and the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will reopen after 48 hours from the declaration of unaudited financial results for the quarter ending 31.12.2025. The date of the Board Meeting for considering these results will be intimated in due course.